

Alan P Kozikowski

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9477161/publications.pdf>

Version: 2024-02-01

81
papers

5,652
citations

81743

39
h-index

79541

73
g-index

81
all docs

81
docs citations

81
times ranked

7077
citing authors

#	ARTICLE	IF	CITATIONS
1	Rational Design and Simple Chemistry Yield a Superior, Neuroprotective HDAC6 Inhibitor, Tubastatin A. <i>Journal of the American Chemical Society</i> , 2010, 132, 10842-10846.	6.6	625
2	HDAC6 inhibitors reverse axonal loss in a mouse model of mutant HSPB1-induced Charcot-Marie-Tooth disease. <i>Nature Medicine</i> , 2011, 17, 968-974.	15.2	405
3	HDAC6 is a target for protection and regeneration following injury in the nervous system. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 19599-19604.	3.3	279
4	Design of Remarkably Simple, Yet Potent Urea-Based Inhibitors of Glutamate Carboxypeptidase II (NAALADase). <i>Journal of Medicinal Chemistry</i> , 2001, 44, 298-301.	2.9	225
5	Synthesis of Urea-Based Inhibitors as Active Site Probes of Glutamate Carboxypeptidase II: Efficacy as Analgesic Agents. <i>Journal of Medicinal Chemistry</i> , 2004, 47, 1729-1738.	2.9	190
6	Use of the Nitrile Oxide Cycloaddition (NOC) Reaction for Molecular Probe Generation: A New Class of Enzyme Selective Histone Deacetylase Inhibitors (HDACIs) Showing Picomolar Activity at HDAC6. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 4370-4373.	2.9	171
7	Why Hydroxamates May Not Be the Best Histone Deacetylase Inhibitors—What Some May Have Forgotten or Would Rather Forget?. <i>ChemMedChem</i> , 2016, 11, 15-21.	1.6	168
8	Selective Histone Deacetylase 6 Inhibitors Bearing Substituted Urea Linkers Inhibit Melanoma Cell Growth. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 9891-9899.	2.9	153
9	Interactions between Human Glutamate Carboxypeptidase II and Urea-Based Inhibitors: Structural Characterization. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 7737-7743.	2.9	138
10	Indole-2-carboxamide-based MmpL3 Inhibitors Show Exceptional Antitubercular Activity in an Animal Model of Tuberculosis Infection. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 6232-6247.	2.9	135
11	Indoleamides are active against drug-resistant <i>Mycobacterium tuberculosis</i> . <i>Nature Communications</i> , 2013, 4, 2907.	5.8	130
12	Divergent roles of histone deacetylase 6 (HDAC6) and histone deacetylase 11 (HDAC11) on the transcriptional regulation of IL10 in antigen presenting cells. <i>Molecular Immunology</i> , 2014, 60, 44-53.	1.0	124
13	Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells. <i>Scientific Reports</i> , 2019, 9, 6136.	1.6	124
14	Preliminary Structure-Activity Relationships and Biological Evaluation of Novel Antitubercular Indolecarboxamide Derivatives Against Drug-Susceptible and Drug-Resistant <i>Mycobacterium tuberculosis</i> Strains. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 4093-4103.	2.9	118
15	Molecular Pathways: Revisiting Glycogen Synthase Kinase-3 β as a Target for the Treatment of Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 1891-1897.	3.2	113
16	Functional Differences in Epigenetic Modulators Superiority of Mercaptoacetamide-Based Histone Deacetylase Inhibitors Relative to Hydroxamates in Cortical Neuron Neuroprotection Studies. <i>Journal of Medicinal Chemistry</i> , 2007, 50, 3054-3061.	2.9	106
17	A Novel Role for Histone Deacetylase 6 in the Regulation of the Tolerogenic STAT3/IL-10 Pathway in APCs. <i>Journal of Immunology</i> , 2014, 193, 2850-2862.	0.4	106
18	Histone deacetylase 6 inhibition improves memory and reduces total tau levels in a mouse model of tau deposition. <i>Alzheimer's Research and Therapy</i> , 2014, 6, 12.	3.0	105

#	ARTICLE	IF	CITATIONS
19	Novel Inhibitors of Human Histone Deacetylase (HDAC) Identified by QSAR Modeling of Known Inhibitors, Virtual Screening, and Experimental Validation. <i>Journal of Chemical Information and Modeling</i> , 2009, 49, 461-476.	2.5	99
20	Highly Potent and Specific GSK-3 β Inhibitors That Block Tau Phosphorylation and Decrease β -Synuclein Protein Expression in a Cellular Model of Parkinson's Disease. <i>ChemMedChem</i> , 2006, 1, 256-266.	1.6	93
21	HDAC6 is a therapeutic target in mutant GARS-induced Charcot-Marie-Tooth disease. <i>Brain</i> , 2018, 141, 673-687.	3.7	93
22	Tubastatin A, an HDAC6 inhibitor, alleviates stroke-induced brain infarction and functional deficits: potential roles of β -tubulin acetylation and FGF-21 up-regulation. <i>Scientific Reports</i> , 2016, 6, 19626.	1.6	84
23	Structure-Based Design Leads to the Identification of Lithium Mimetics That Block Mania-like Effects in Rodents. Possible New GSK-3 β Therapies for Bipolar Disorders. <i>Journal of the American Chemical Society</i> , 2007, 129, 8328-8332.	6.6	83
24	Histone/protein deacetylase 11 targeting promotes Foxp3+ Treg function. <i>Scientific Reports</i> , 2017, 7, 8626.	1.6	64
25	Chemistry and biology of mercaptoacetamides as novel histone deacetylase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2005, 15, 1389-1392.	1.0	62
26	Targeting Mycolic Acid Transport by Indole-2-carboxamides for the Treatment of <i>Mycobacterium abscessus</i> Infections. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 5876-5888.	2.9	61
27	Discovery of a New Isoxazole-3-hydroxamate-Based Histone Deacetylase 6 Inhibitor SS-208 with Antitumor Activity in Syngeneic Melanoma Mouse Models. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 8557-8577.	2.9	61
28	Bicyclic-Capped Histone Deacetylase 6 Inhibitors with Improved Activity in a Model of Axonal Charcot-Marie-Tooth Disease. <i>ACS Chemical Neuroscience</i> , 2016, 7, 240-258.	1.7	60
29	A patent review of histone deacetylase 6 inhibitors in neurodegenerative diseases (2014-2019). <i>Expert Opinion on Therapeutic Patents</i> , 2020, 30, 121-136.	2.4	56
30	GSK-3 inhibition overcomes chemoresistance in human breast cancer. <i>Cancer Letters</i> , 2016, 380, 384-392.	3.2	55
31	Selective 5-Hydroxytryptamine 2C Receptor Agonists Derived from the Lead Compound Tranylcypromine: Identification of Drugs with Antidepressant-Like Action. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 1885-1902.	2.9	54
32	Chemistry, Biology, and QSAR Studies of Substituted Biaryl Hydroxamates and Mercaptoacetamides as HDAC Inhibitors—Nanomolar Potency Inhibitors of Pancreatic Cancer Cell Growth. <i>ChemMedChem</i> , 2008, 3, 487-501.	1.6	50
33	Brain Penetrable Histone Deacetylase 6 Inhibitor SW-100 Ameliorates Memory and Learning Impairments in a Mouse Model of Fragile X Syndrome. <i>ACS Chemical Neuroscience</i> , 2019, 10, 1679-1695.	1.7	50
34	Phosphatidylinositol Ether Lipid Analogues That Inhibit AKT Also Independently Activate the Stress Kinase, p38 β , through MKK3/6-independent and -dependent Mechanisms. <i>Journal of Biological Chemistry</i> , 2007, 282, 27020-27029.	1.6	49
35	A selective histone deacetylase-6 inhibitor improves BDNF trafficking in hippocampal neurons from Mecn2 knockout mice: implications for Rett syndrome. <i>Frontiers in Cellular Neuroscience</i> , 2014, 8, 68.	1.8	47
36	Structural and in Vivo Characterization of Tubastatin A, a Widely Used Histone Deacetylase 6 Inhibitor. <i>ACS Medicinal Chemistry Letters</i> , 2020, 11, 706-712.	1.3	47

#	ARTICLE	IF	CITATIONS
37	Development of Small Molecules that Specifically Inhibit the D-loop Activity of RAD51. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 4511-4525.	2.9	45
38	GSK-3 β Governs Inflammation-Induced NFATc2 Signaling Hubs to Promote Pancreatic Cancer Progression. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 491-502.	1.9	44
39	Active Benzimidazole Derivatives Targeting the MmpL3 Transporter in <i>Mycobacterium abscessus</i> . <i>ACS Infectious Diseases</i> , 2020, 6, 324-337.	1.8	44
40	Searching for Disease Modifiers—PKC Activation and HDAC Inhibition—A Dual Drug Approach to Alzheimer's Disease that Decreases A β Production while Blocking Oxidative Stress. <i>ChemMedChem</i> , 2009, 4, 1095-1105.	1.6	42
41	5-HT _{2C} Agonists Modulate Schizophrenia-Like Behaviors in Mice. <i>Neuropsychopharmacology</i> , 2017, 42, 2163-2177.	2.8	42
42	The RAD51-Stimulatory Compound RS-1 Can Exploit the RAD51 Overexpression That Exists in Cancer Cells and Tumors. <i>Cancer Research</i> , 2014, 74, 3546-3555.	0.4	40
43	HDAC6 inhibition promotes α -tubulin acetylation and ameliorates CMT2A peripheral neuropathy in mice. <i>Experimental Neurology</i> , 2020, 328, 113281.	2.0	39
44	Isoxazole moiety in the linker region of HDAC inhibitors adjacent to the Zn-chelating group: Effects on HDAC biology and antiproliferative activity. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 3023-3026.	1.0	37
45	Identification of a Glycogen Synthase Kinase-3 β Inhibitor that Attenuates Hyperactivity in CLOCK Mutant Mice. <i>ChemMedChem</i> , 2011, 6, 1593-1602.	1.6	36
46	Thiol-Based Potent and Selective HDAC6 Inhibitors Promote Tubulin Acetylation and T-Regulatory Cell Suppressive Function. <i>ACS Medicinal Chemistry Letters</i> , 2015, 6, 1156-1161.	1.3	36
47	Recent Developments Using Small Molecules to Target RAD51: How to Best Modulate RAD51 for Anticancer Therapy?. <i>ChemMedChem</i> , 2016, 11, 2468-2473.	1.6	36
48	Chemistry and Pharmacology of Nicotinic Ligands Based on 6-((5-(Azetidin-2-ylmethoxy)pyridin-3-yl)hexyl)cyclopentanol (AMOP-CH ₂ OH) for Possible Use in Depression. <i>ChemMedChem</i> , 2009, 4, 1279-1291.	1.3	35
49	Combination Treatment with the GSK-3 Inhibitor 9-ING-41 and CCNU Cures Orthotopic Chemoresistant Glioblastoma in Patient-Derived Xenograft Models. <i>Translational Oncology</i> , 2017, 10, 669-678.	1.7	32
50	Optimization of 2-Phenylcyclopropylmethylamines as Selective Serotonin 2C Receptor Agonists and Their Evaluation as Potential Antipsychotic Agents. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 1992-2002.	2.9	31
51	Design and Synthesis of Mercaptoacetamides as Potent, Selective, and Brain Permeable Histone Deacetylase 6 Inhibitors. <i>ACS Medicinal Chemistry Letters</i> , 2017, 8, 510-515.	1.3	30
52	Chiral Mercaptoacetamides Display Enantioselective Inhibition of Histone Deacetylase...6 and Exhibit Neuroprotection in Cortical Neuron Models of Oxidative Stress. <i>ChemMedChem</i> , 2012, 7, 425-439.	1.6	29
53	Identification of HDAC6-Selective Inhibitors of Low Cancer Cell Cytotoxicity. <i>ChemMedChem</i> , 2016, 11, 81-92.	1.6	29
54	Rational Design of Suprastat: A Novel Selective Histone Deacetylase 6 Inhibitor with the Ability to Potentiate Immunotherapy in Melanoma Models. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 10246-10262.	2.9	29

#	ARTICLE	IF	CITATIONS
55	Design and Discovery of Functionally Selective Serotonin 2C (5-HT _{2C}) Receptor Agonists. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 9866-9880.	2.9	28
56	Mercaptoacetamide: A promising zinc-binding group for the discovery of selective histone deacetylase 6 inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2021, 209, 112887.	2.6	28
57	Chemical Medicine: Novel 10-Substituted Cytisine Derivatives with Increased Selectivity for $\alpha 4\beta 2$ Nicotinic Acetylcholine Receptors. <i>ChemMedChem</i> , 2007, 2, 1157-1161.	1.6	27
58	Further Advances in Optimizing (2-Phenylcyclopropyl)methylamines as Novel Serotonin 2C Agonists: Effects on Hyperlocomotion, Prepulse Inhibition, and Cognition Models. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 578-591.	2.9	26
59	Mutation of <i>Rv2887</i> , a <i>marR</i> -Like Gene, Confers Mycobacterium tuberculosis Resistance to an Imidazopyridine-Based Agent. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 6873-6881.	1.4	25
60	Synthesis and Pharmacological Evaluation of Selective Histone Deacetylase 6 Inhibitors in Melanoma Models. <i>ACS Medicinal Chemistry Letters</i> , 2017, 8, 1031-1036.	1.3	25
61	HTS and Rational Drug Design to Generate a Class of 5-HT _{2C} -Selective Ligands for Possible Use in Schizophrenia. <i>ChemMedChem</i> , 2010, 5, 1221-1225.	1.6	24
62	Molecular Basis for the Selective Inhibition of Histone Deacetylase 6 by a Mercaptoacetamide Inhibitor. <i>ACS Medicinal Chemistry Letters</i> , 2018, 9, 1301-1305.	1.3	24
63	Discovery of <i>N</i> -Substituted (2-Phenylcyclopropyl)methylamines as Functionally Selective Serotonin 2C Receptor Agonists for Potential Use as Antipsychotic Medications. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 6273-6288.	2.9	19
64	We Need 2C but Not 2B: Developing Serotonin 2C (5-HT _{2C}) Receptor Agonists for the Treatment of CNS Disorders. <i>ChemMedChem</i> , 2015, 10, 1963-1967.	1.6	18
65	Controlling Extra- and Intramacrophagic Mycobacterium abscessus by Targeting Mycolic Acid Transport. <i>Frontiers in Cellular and Infection Microbiology</i> , 2017, 7, 388.	1.8	18
66	Tetrahydroquinoline-Capped Histone Deacetylase 6 Inhibitor SW-101 Ameliorates Pathological Phenotypes in a Charcot-Marie-Tooth Type 2A Mouse Model. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 4810-4840.	2.9	17
67	Rational Drug Design Leading to the Identification of a Potent 5-HT _{2C} Agonist Lacking 5-HT _{2B} Activity. <i>ACS Medicinal Chemistry Letters</i> , 2011, 2, 929-932.	1.3	15
68	Design and synthesis of (2-(5-chloro-2,2-dimethyl-2,3-dihydrobenzofuran-7-yl)cyclopropyl)methanamine as a selective serotonin 2C agonist. <i>Tetrahedron Letters</i> , 2015, 56, 3420-3422.	0.7	15
69	Design and Synthesis of Bitopic 2-Phenylcyclopropylmethylamine (PCPMA) Derivatives as Selective Dopamine D3 Receptor Ligands. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 4579-4602.	2.9	15
70	Exploration of the labeling of [¹¹ C]tubastatin A at the hydroxamic acid site with [¹¹ C]carbon monoxide. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2016, 59, 9-13.	0.5	14
71	Synthesis and biological evaluation of novel hybrids of highly potent and selective $\alpha 4\beta 2$ -Nicotinic acetylcholine receptor (nAChR) partial agonists. <i>European Journal of Medicinal Chemistry</i> , 2016, 124, 689-697.	2.6	14
72	Rational Design and Development of Radiation-Sensitizing Histone Deacetylase Inhibitors. <i>Chemistry and Biodiversity</i> , 2005, 2, 1452-1461.	1.0	12

#	ARTICLE	IF	CITATIONS
73	Synergistic Interactions of Indole-2-Carboxamides and β -Lactam Antibiotics against Mycobacterium abscessus. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	12
74	Acetylenic Pyridines for Use in PET Imaging of Nicotinic Receptors. <i>ChemMedChem</i> , 2007, 2, 54-57.	1.6	11
75	Enantiopure Cyclopropane-Bearing Pyridyldiazabicyclo[3.3.0]octanes as Selective $\alpha 4\beta 2$ -nAChR Ligands. <i>ACS Medicinal Chemistry Letters</i> , 2014, 5, 1196-1201.	1.3	8
76	Synthesis and Behavioral Studies of Chiral Cyclopropanes as Selective $\alpha 4\beta 2$ -Nicotinic Acetylcholine Receptor Partial Agonists Exhibiting an Antidepressant Profile. Part III. <i>ACS Chemical Neuroscience</i> , 2016, 7, 811-822.	1.7	8
77	2-Amino adipic Acid α -C(O)- α -Glutamate Based Prostate-Specific Membrane Antigen Ligands for Potential Use as Theranostics. <i>ACS Medicinal Chemistry Letters</i> , 2018, 9, 1099-1104.	1.3	6
78	Design of fluorinated cyclopropane derivatives of 2-phenylcyclopropylmethylamine leading to identification of a selective serotonin 2C (5-HT _{2C}) receptor agonist without 5-HT _{2B} agonism. <i>European Journal of Medicinal Chemistry</i> , 2019, 182, 111626.	2.6	3
79	On the path from chemistry to neuroscience: Early explorations in chemical medicine under the mentorship of Dr. Erminio Costa, a neuroscientist with a big brain and a bigger heart. <i>Pharmacological Research</i> , 2011, 64, 327-329.	3.1	1
80	Effective Collaborations: How to Protect Yourself, Your Collaborators, and Your Data. <i>ChemMedChem</i> , 2011, 6, 411-414.	1.6	0
81	A Novel Role for Histone Deacetylase 6 (HDAC6) in the Regulation of IL-10 and Immune Tolerance Mediated by Antigen-Presenting Cells (APCs).. <i>Blood</i> , 2009, 114, 1360-1360.	0.6	0